<DOC>
	<DOCNO>NCT01708057</DOCNO>
	<brief_summary>This study Chronic Obstructive Pulmonary Disease ( COPD ) patient investigate bronchodilatory effect AZD8683 . AZD8683 test versus placebo active comparator .</brief_summary>
	<brief_title>A Single-dose Study Investigate Effects 4 Different Doses Inhaled AZD8683 Chronic Obstructive Pulmonary Disease ( COPD ) Patients</brief_title>
	<detailed_description>A randomised , double-blind placebo- active-controlled , multi-centre , 6-way cross-over , single-dose phase IIa study investigate bronchodilatory systemic effect 4 different dos inhale AZD8683 patient Chronic Obstructive Pulmonary Disease ( COPD ) .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Male female , age ≥ 40 year Visit 1 . Women must nonchildbearing potential must stable highly effective contraceptive method least 3 month prior Visit 1 willing continue followup Clinical diagnosis COPD 1 year Visit 1 FEV1 ≥ 30 &lt; 80 % predict normal value ( postbronchodilator ) Visit 2 postbronchodilator FEV1/FVC &lt; 70 % Reversible airway obstruction Significant disease disorder , opinion Investigator , may either put patient risk participation study , influence result study , patient 's ability participate study . An exacerbation COPD ( define use oral/parenteral glucocorticosteroids ( GCS ) and/or antibiotic and/or hospitalisation relate COPD ) within 6 week Visit 1or enrolment period Treatment systemic GCS within 6 week Visit 2 enrolment period Respiratory tract infection clinical relevance within 30 day Visit 4 , judge Investigator Longterm oxygen therapy , judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic obstructive pulmonary disease</keyword>
</DOC>